# OnCo record paper-keynote-177-nejm-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-keynote-177-nejm-2020" ;
schema:name "KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer"@en ;
schema:description "For the roughly 5% of metastatic bowel cancers with defective DNA mismatch repair, pembrolizumab alone lengthened the time without progression compared with chemotherapy, with far fewer severe side effects, and 83% of responses lasted two years or more. It made first-line pembrolizumab the standard for this group."@en ;
schema:url ;
schema:dateModified "2026-09-08"^^xsd:date ;
schema:citation , , , ;
schema:sameAs ;
schema:datePublished "2020"^^xsd:gYear ;
schema:author "Andre T, Shiu KK, Kim TW, et al." ;
onco:related , , , ;
onco:cancers , ;
onco:sections ;
onco:technologies , , ;
onco:targets , ;
onco:drugs ;
onco:companies ;
onco:pathways , ;
onco:terms , , , , , , ;
onco:trials ;
onco:people , , , , , , ;
onco:bottlenecks , , ;
onco:journals .